Parkinson’s patients ‘owed’ more research into using cancer drug as treatment

News

Author: AdminPublished: 2 November 2015

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

News image

A small clinical trial showed that cancer drug Nilotinib may reverse late-stage Parkinson’s disease, potentially enabling participants to speak and walk again for the first time in years.

President and co-founder of The Cure Parkinson’s Trust, Tom Isaacs, has called for a close follow up of this small study to ensure that any opportunity for a breakthrough in the treatment of Parkinson’s is not missed.

Isaacs said: ‘Nilotinib is a case in point. When people with Parkinson’s volunteer for clinical trials and feel the type of marked improvements to their symptoms and wellbeing as those reported in this study, we owe it to them, and indeed everyone, to follow the results up as quickly and as rigorously as possible.”

Go Back

Share this story

Comments


Related articles


Smiling doctor and patients

PD in Practice

Are you in a patient-style ‘rut’? How to talk so your doctor listens

How to recognise patient styles to improve doctor relationships

READ MORE
Moving Day with confetti

Global update

Exclusive interview: John Lehr and James Beck of the Parkinson’s Foundation

Meet the Parkinson’s Foundation CEO and Chief Scientific Officer

READ MORE
American Ninja Warrior lead

Interviews

Overcoming obstacles: why Parkinson’s won’t stop me competing on Ninja Warrior

Parkinson’s patient hopes to win ‘American Ninja Warrior’

READ MORE